AMPH

#2181
Amphastar Pharmaceuticals, Inc. - Common Stock
18.8 5 USD
+9666.84%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
18.85
18.85
Faixa anual
0.18
29.52
Mudança diária
+9666.84%
Mudança mensal
-12.85%
Mudança em 6 meses
-31.30%
Mudança anual
-22.68%
Fechamento anterior
0.1 9
Open
18.8 5
Mínimo
18.8 5
High
18.8 5
Volume
93
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 831.15 M
  • Employee 1 976
  • Founded 1996
  • CEO N/A
  • Website www.amphastar.com
  • Headquarter California, United States
  • FIGI BBG000BW90S6
  • Industry Fabricantes de medicamentos - especializados e genéricos
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
11.8
Índice preço/fluxo de caixa
1.29

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.

Notícias